Tumor Ablation Market

The tumor ablation market was valued at $1.6 billion in 2023, and is estimated to reach $7.5 billion by 2035, growing at a CAGR of 13.6% from 2024 to 2035. Tumor ablation is a medical procedure used to treat cancer by destroying tumor cells without the need for traditional surgery. This technique involves the targeted application of energy to the tumor site to destroy or shrink cancerous growths. Several methods are used for tumor ablation, including thermal ablation techniques such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. These methods work by either heating or freezing the tumor cells, effectively killing them or halting their growth. Tumor ablation is typically used for tumors that are difficult to reach surgically, located in sensitive areas, or for patients who may not be candidates for conventional surgery due to their health conditions. It serves as a complementary treatment alongside other cancer therapies such as chemotherapy or radiation. The rising global prevalence of cancer is a major factor contributing to the growth of the tumor ablation market.

For instance, the World Health Organization (WHO), predicted 35 million new cancer cases in 2050, a 77% increase from the estimated 20 million cases in 2022. This growing incidence of cancer increased the demand for effective treatment options, including tumor ablation. Ablation therapies are particularly useful in treating tumors that are difficult to access surgically or those that are located in sensitive areas, such as the liver, lungs, kidneys, and prostate. As the number of cancer patients continues to rise, the need for innovative and less invasive treatment options, such as tumor ablation, are expected to continue to grow. In addition, rise in demand for minimally invasive procedures is another significant driver for the tumor ablation market. As patients and healthcare providers become more aware of the benefits of minimally invasive techniques, such as reduced hospital stays, faster recovery, and fewer complications, the preference for these procedures has grown. Tumor ablation procedures, being minimally invasive, cater to this demand, providing a treatment option that are performed with smaller incisions or even through percutaneous (needle-based) approaches. These factors make tumor ablation particularly appealing to both patients and healthcare providers, leading to a shift toward these therapies in clinical practice. Furthermore, rises in government initiatives aimed at cancer research and treatment are another factor fueling market growth.

Many governments and organizations are increasing funding for cancer-related research, which has led to the development of more effective and precise tumor ablation technologies. The U.S. National Cancer Institute (NCI), for example, has been actively involved in funding studies related to innovative cancer treatments, including tumor ablation. In addition, several regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are working to streamline the approval processes for new tumor ablation technologies, which has encouraged further market development. For instance, in March 2024, Medtronic plc, a global leader in healthcare technology announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. Thus, rise in the number of product approvals further drives market growth. However, high cost of ablation procedures and equipment, which limits accessibility, particularly in low- and middleincome countries, thereby restricts market growth. These procedures often require advanced technology, which can be expensive for healthcare providers to adopt and maintain, making it difficult for many patients to afford. In addition, the limited reimbursement policies in certain regions can restrict patient access to these therapies. Another restraint is the potential for complications associated with ablation procedures, such as injury to surrounding healthy tissues or inadequate treatment of larger or more complex tumors which further limits the market growth. 

On the other hand, the ongoing advancements in ablation technologies, such as the development of more precise and efficient devices, create opportunities to improve treatment outcomes and expand the range of treatable tumors. There is also considerable potential for market expansion in emerging economies, where improving healthcare infrastructure and increasing awareness about cancer treatments are driving the adoption of advanced medical technologies such as tumor ablation. These opportunities collectively provide a strong foundation for the continued growth of the tumor ablation market. The tumor ablation market is segmented into technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other ablation technologies. By treatment, the market is segregated into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, the market is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, bone cancer, and others.

Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global tumor ablation market are AngioDynamics, Inc., Olympus Corporation, Medtronic Plc, Bioventus Inc.Integra LifeSciences Holdings Corporation, Johnson & Johnson, Boston Scientific Corporation, Stryker Corporation, IceCure Medical Ltd., and Siemens. Key players operating in the market have adopted product approval, agreement, clinical trial, expansion, and acquisition as their key strategies to expand their product portfolio. For instance, in April 2021, Siemens Healthineers AG announced that it successfully completed the acquisition of Varian Medical Systems, Inc. The acquisition was previously announced on August 2, 2020. This acquisition enhanced Siemens Healthineers capabilities in imaging, laboratory diagnostics, artificial intelligence, and treatment solutions, thereby expanding its product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2023 to 2035 to identify the prevailing tumor ablation market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technology

Radiofrequency Ablation
Microwave Ablation
Cryoablation
Irreversible Electroporation Ablation
Other Ablation Technologies

By Treatment

Surgical Ablation
Laparoscopic Ablation
Percutaneous Ablation

By Application

Kidney Cancer
Liver Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
Bone Cancer
Other

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest Of La
Key Market Players
Bioventus Inc.
Medtronic Plc
Johnson & Johnson
IceCure Medical Ltd.
Siemens
AngioDynamics, Inc.
Stryker Corporation
Olympus Corporation
Integra LifeSciences Holdings Corporation
Boston Scientific CorporationThe research methodology of the global market involves extensive primary and secondary research. Primary research includes about over 12 hours of interviews and discussion with a wide range of stakeholders, including upstream and downstream participants. The primary research typically is the bulk of our research efforts; however, coherently supported by extensive secondary research. Researchers have reviewed over 6,765 product literatures, industry releases, annual reports, and other such documents of key industry participants to obtain better market understanding and gain competitive intelligence. In addition, authentic industry journals, trade associations' releases,and government websites have also been reviewed for generating high-value industry insights. Show more